



GlaxoSmithKline Pharmaceuticals Limited
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

1st February 2024

To,

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, we would like to inform you that the Company has received a Order dated 31st January 2024 from Income Tax Department. The relevant details to be disclosed is as under:

Name of the Authority	Income Tax Authority
Nature and details of the action(s) taken, initiated or order(s) passed	Assessment Order u/s 143(3) r.w. Section 144C (3) read with sec. 144B for the AY 2021-2022.
Order date	Order dt. 31 January 2024 recd. on the same day
Details of the violation(s)/ contravention(s) committed or alleged to be committed	The company has received a Final Assessment Order for the AY: 2021-2022 from the Assessing Authority by disallowing certain Expenses and making Adjustments under Transfer Pricing.
Quantum of Claims, if any	Income Tax liability of INR 16.84 Crores
Impact on financial, operation, or other activities of the listed entity, quantifiable in monetary terms to the extent possible	The Income Tax Authority has issued the Final Assessment order u/s 143(3) r.w. Section 144C (3) read with sec. 144B for the AY 21-22 making adjustments on Transfer Pricing and some expense. The Company would file a further appeal to the 1 st appellate authority in another 30 days challenging the Assessing Officer Order. There is no impact on the financial, operation, or other activities of the Company due to the Assessment Order.

Kindly take the same on the record.

Thanking you,

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

CIN: L24239MH1924PLC001151